[Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].
Severe congestive cardiac failure developed in a few weeks in a 44 year old man who had undergone porto-caval anastamosis for post-hepatitis cirrhosis one year previously and then treated for anaemia by repeated blood transfusion and chronic daily oral iron therapy. Infiltrative, congestive and restrictive cardiomyopathy was diagnosed in the presence of global cardiomegaly, electrocardiographic changes (microvoltage, diffuse ST-T wave changes), echocardiographic appearances (dilatation of the left ventricle, with hypertrophic and hypokinetic walls), and hemodynamic signs of adiastole with equalisation of filling pressures at 15 mmHg and a cardiac index of 1,88 l/min/m2. Cardiac haemochromatosis was confirmed by the laboratory (serum iron: 35 mumol/l; siderophilin saturation: 100 p. 100; serum ferritin: 1854 ng/ml; induced siderouria: 51 mg/24 hours) and histological findings (endomyocardial biopsy showing pigment overload). The absence of a family history, of homozygote A3 antigen, of diabetes, of iron overload on hepatic biopsy one year previously, excluded the diagnosis of familial idiopathic haemochromatosis. A secondary form of the disease was diagnosed on a possible genetic predisposition (heterozygote A3 antigen) and on environmental factors (blood transfusions, iron therapy, cirrhosis, alcoholism and perhaps the porto-caval anastamosis. Cardiac haemochromatosis was cured in this case by iron chelating therapy comprising daily subcutaneous infusions of 2 g of desferrioxamine for 2 months. The cure was confirmed by regression of the signs of clinical cardiac failure and of cardiomegaly, the increase in QRS voltages and the near normalisation of the hemodynamic and laboratory findings.
D000328:Adult; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000209:etiology*; D002311:Cardiomyopathy, Dilated / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D003676:Deferoxamine / Q000627:therapeutic use; D003971:Diastole; D004452:Echocardiography; D004562:Electrocardiography; D006333:Heart Failure / Q000150:complications*; D006432:Hemochromatosis / Q000150:complications* / Q000209:etiology; D006801:Humans; D008297:Male; D009206:Myocardium / Q000473:pathology
D003676:Deferoxamine
Adiastolie par hémochromatose cardiaque secondaire. Guérison par traitement chélateur du fer.